| Title |
Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
|
|---|---|
| Published in |
Diabetes Therapy, May 2013
|
| DOI | 10.1007/s13300-013-0024-0 |
| Pubmed ID | |
| Authors |
Samuel S. Engel, Elizabeth Round, Gregory T. Golm, Keith D. Kaufman, Barry J. Goldstein |
| Abstract |
In a previous pooled analysis of 19 double-blind clinical studies conducted by Merck, which included data available as of July 2009 on 10,246 patients with type 2 diabetes (T2DM), treatment with sitagliptin was shown to be generally well tolerated compared with treatment with control agents. As the sitagliptin clinical development program continues, additional studies with sitagliptin have been completed. The present analysis updates the safety and tolerability assessment of sitagliptin by examining pooled data from 25 double-blind clinical studies. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 5 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 60% |
| Practitioners (doctors, other healthcare professionals) | 1 | 20% |
| Science communicators (journalists, bloggers, editors) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 105 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | <1% |
| France | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 102 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 21 | 20% |
| Researcher | 14 | 13% |
| Student > Master | 13 | 12% |
| Student > Bachelor | 11 | 10% |
| Student > Doctoral Student | 9 | 9% |
| Other | 19 | 18% |
| Unknown | 18 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 49 | 47% |
| Pharmacology, Toxicology and Pharmaceutical Science | 12 | 11% |
| Agricultural and Biological Sciences | 10 | 10% |
| Biochemistry, Genetics and Molecular Biology | 6 | 6% |
| Nursing and Health Professions | 2 | 2% |
| Other | 5 | 5% |
| Unknown | 21 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 27. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 November 2015.
All research outputs
#1,204,498
of 22,711,242 outputs
Outputs from Diabetes Therapy
#38
of 1,010 outputs
Outputs of similar age
#10,458
of 195,532 outputs
Outputs of similar age from Diabetes Therapy
#1
of 9 outputs
Altmetric has tracked 22,711,242 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,010 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.4. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 195,532 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them